Abstract Details

Title Serum Neurofilament Light Chain Levels as a Biomarker of Disease Activity and Treatment Response in Patients with Progressive and Relapsing Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P1 - Poster Session 1 (8:00 AM-9:00 AM)

Poster/Presentation
Number 3-009

Objective

To assess the value of serum neurofilament light chain (NfL) as a biomarker of disease activity and treatment response in Western Australian patients with multiple sclerosis (MS).

Background

NfL is a less costly, blood-based biomarker suitable for the longitudinal monitoring of disease status and response to treatment. NfL levels in the CSF and blood are reflecting the degree of axonal damage in MS.

Design/Methods

Serum NfL levels were measured in 542 patients with demyelinating disease, using single-molecule array technology (SIMOA). Treatment strategies were classified as “no treatment”, “injectable” and “high efficacy”. The Expanded Disability Status Scale (EDSS) score and patients’ demographics were also analysed.

Results Higher levels of NfL were associated with higher levels of disability. There was a statistically significant difference in NfL levels between early disease (CIS/RRMS) and progressive disease (PPMS/SPMS), without treatment (35.2 ± 4.5 vs 42.0 ± 3.9, p<0.01, adjusted for age). Therapy significantly reduced NfL levels in RRMS compared to “no treatment” (24.4 ± 1.3 vs 36.9 ± 5.1, p<0.01, adjusted for age). Both “injectable” and “high efficacy” therapies reduced serum NfL levels in RRMS patients, however, a statistically significant difference was noted only with “high efficacy” treatments (23.3 ± 1.5 vs 36.9 ±5.1).

Conclusions

Our findings support the potential value of serum NfL as a measure of disease activity and treatment response in multiple sclerosis.

Authors/Disclosures
Marzena Pedrini, PhD (Perron Institute for Neurological and Translational Science) PRESENTER	Dr. Pedrini has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Jens Kuhle, MD	Dr. Kuhle has nothing to disclose.
Allan G. Kermode, MD, MBBS, FRACP (SJOG Clinic, Suite 314)	Dr. Kermode has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Kermode has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche.

��ɫ��

��ɫ��